News & Updates

Show Multimedia Only

PREVENT equations identify individuals who will benefit from intensive SBP control

07 Nov 2025

The reduction in relative risk with intensive vs standard systolic blood pressure (SBP) treatment among individuals without baseline cardiovascular disease (CVD) is consistent across the risk strata using the PREVENT* equations, as shown in the SPRINT study.

PREVENT equations identify individuals who will benefit from intensive SBP control

07 Nov 2025

Bemarituzumab extends survival in FGFR2b-overexpressing gastric cancer

07 Nov 2025 by

The use of bemarituzumab in combination with chemotherapy provides statistically significant survival benefits among patients with advanced or metastatic FGFR2b-overexpressing gastric or gastroesophageal junction cancer (G/GEJC) in the primary analysis of the phase III FORTITUDE-101 trial.

Bemarituzumab extends survival in FGFR2b-overexpressing gastric cancer

07 Nov 2025

Breastfeeding improves health outcomes in mothers, children

07 Nov 2025

Breastfeeding provides several benefits to mothers and their children, including reduced risks in sudden infant death syndrome and allergic rhinitis, as well as improved physical fitness, reports a study.

Breastfeeding improves health outcomes in mothers, children

07 Nov 2025

Retinal ageing marker may predict cognitive decline, dementia

07 Nov 2025 by

A study from Singapore underscores the potential of a retinal ageing biomarker derived from retinal photography as a prognostic biomarker for cognitive decline and incident dementia.

Retinal ageing marker may predict cognitive decline, dementia

07 Nov 2025

Postpartum maternal psychological distress tied to neurodevelopmental delay in toddlers

07 Nov 2025

Toddlers born to mothers with psychological distress through 1 year postpartum are more likely to have neurodevelopmental delay, according to a study.

Postpartum maternal psychological distress tied to neurodevelopmental delay in toddlers

07 Nov 2025

First-line sacituzumab govitecan ups PFS in metastatic TBNC

07 Nov 2025 by

First-line treatment with sacituzumab govitecan, an antibody drug conjugate, significantly improved progression-free survival (PFS) compared with chemotherapy in patients with metastatic triple-negative breast cancer (TNBC), according to the ASCENT-03 trial presented at ESMO 2025.

First-line sacituzumab govitecan ups PFS in metastatic TBNC

07 Nov 2025

Patients with serious mental illness at high risk of postacute sequelae of SARS-CoV-2

06 Nov 2025

Among patients who sustained COVID-19 infection, the risk of postacute sequelae of SARS-CoV-2 (PASC) is high in the presence of a serious mental illness, according to a study.

Patients with serious mental illness at high risk of postacute sequelae of SARS-CoV-2

06 Nov 2025

Dengue may increase susceptibility to subsequent cardiac events

06 Nov 2025 by

Individuals who sustained an acute dengue virus infection are predisposed to cardiovascular events up to 30 days after infection, although the excess risk was modest, according to a study from Singapore.

Dengue may increase susceptibility to subsequent cardiac events

06 Nov 2025

Ultraprocessed food consumption ups risk of suicide attempt

06 Nov 2025

Regular consumption of ultraprocessed foods (UPF) appears to elevate the risk of suicide attempts (SAs), suggests a study. This association is partially mediated by inflammatory index levels.

Ultraprocessed food consumption ups risk of suicide attempt

06 Nov 2025

Datopotamab deruxtecan improves survival in breast cancer patients not eligible for immunotherapy

06 Nov 2025 by

First-line treatment with datopotamab deruxtecan (Dato-DXd) results in statistically significant and clinically meaningful improvements in overall survival (OS) and progression-free survival (PFS) compared with chemotherapy in patients with locally recurrent inoperable or metastatic triple-negative breast cancer (TNBC), as shown by the results of the phase III TROPION-Breast02 trial.

Datopotamab deruxtecan improves survival in breast cancer patients not eligible for immunotherapy

06 Nov 2025

News & Updates

Filter by Specialty:

Specialty:

PREVENT equations identify individuals who will benefit from intensive SBP control

PREVENT equations identify individuals who will benefit from intensive SBP control

Bemarituzumab extends survival in FGFR2b-overexpressing gastric cancer

Bemarituzumab extends survival in FGFR2b-overexpressing gastric cancer

Breastfeeding improves health outcomes in mothers, children

Breastfeeding improves health outcomes in mothers, children

Retinal ageing marker may predict cognitive decline, dementia

Retinal ageing marker may predict cognitive decline, dementia

Postpartum maternal psychological distress tied to neurodevelopmental delay in toddlers

Postpartum maternal psychological distress tied to neurodevelopmental delay in toddlers

First-line sacituzumab govitecan ups PFS in metastatic TBNC

First-line sacituzumab govitecan ups PFS in metastatic TBNC

Patients with serious mental illness at high risk of postacute sequelae of SARS-CoV-2

Patients with serious mental illness at high risk of postacute sequelae of SARS-CoV-2

Dengue may increase susceptibility to subsequent cardiac events

Dengue may increase susceptibility to subsequent cardiac events

Ultraprocessed food consumption ups risk of suicide attempt

Ultraprocessed food consumption ups risk of suicide attempt

Datopotamab deruxtecan improves survival in breast cancer patients not eligible for immunotherapy

Datopotamab deruxtecan improves survival in breast cancer patients not eligible for immunotherapy